Information sourced from NIH Research Portfolio Online Reporting Tools (RePORT)
Aspergillus polysaccharide antigens are excreted in urine in course of the lung disease, invasive pulmonary aspergillosis. About 200,000 people in the U.S. are at risk for this disease, which kills 40-80% of people who get it.
Using a novel monoclonal antibody that detects Aspergillus antigens in urine, PearlDx developed a prototype diagnostic test that detects antigens early during the course of disease.
Pearl Diagnostics, Inc. received an NIAID STTR Phase I grant to define performance characteristics of the prototype in high-risk patients.